Baseline characteristics of thrombophilia screen-positive patients (n=50)
| Characteristics | All (n=50) | Positive APA (n=28) | FVL/PGM genotype (n=13) | Protein C, S or AT deficiency (n=10) |
| Age, mean (SD), years | 49 (9.2) | 50 (7) | 50 (5) | 49 (9) |
| Male sex, n (%) | 28 (57) | 18 (37) | 7 (14) | 4 (8) |
| Hypertension, n (%) | 25 (51) | 12 (24) | 6 (12) | 6 (12) |
| Diabetes mellitus, n (%) | 6 (12) | 2 (4) | 4 (8) | 0 |
| Hyperlipidaemia, n (%) | 11 (22) | 5 (10) | 3 (6) | 3 (6) |
| Smoking, n (%) | 18 (36) | 12 (22) | 3 (6) | 3 (6) |
| Peripheral vascular disease, n (%) | 1 (2) | 1 (2) | 0 | 0 |
| Previous stroke/TIA, n (%) | 7 (14) | 2 (4) | 4 (8) | 1 (2) |
| Family history of stroke/IHD, n (%) | 8 (16) | 4 (8) | 2 (4) | 2 (4) |
| History of VTE, n (%) | 1 (2) | 1 (2) | 1 (2) | 0 |
| Ischaemic heart disease, n (%) | 4 (8) | 2 (4) | 2 (4) | 0 |
| Atrial fibrillation*, n (%) | 1 (2) | 1 (2) | 1 (2) | 0 |
| Patent foramen ovale, n (%) | 4† (8) | 2 (4) | 2 (4) | 1 (2) |
| Other cardiac disease, n (%) | 3‡ (6) | 3 (6) | 0 | 0 |
| History of cancer, n (%) | 3 (6) | 2 (4) | 2 (4) | 0 |
*Atrial fibrillation detected by either 12-lead ECG or Holter.
†One case both with FVL mutation and raised APA.
‡Cases with metallic valve replacement and cardiomyopathy.
APA, antiphospholipid antibodies; AT, antithrombin; FVL, factor V Leiden; IHD, ischaemic heart disease; PGM, prothrombin G20210A mutation; TIA, transient ischaemic attack; VTE, venous thromboembolism.